首页 > 最新文献

Canadian respiratory journal最新文献

英文 中文
Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors 使用第一代或第二代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂治疗临床 IIIB 期或 IIIC 期肺癌和表皮生长因子受体(EGFR)突变患者的最终放疗疗效
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-03-05 DOI: 10.1155/2024/8889536
Chih-Yen Tu, Te-Chun Hsia, Ying-Chun Lin, Ji-An Liang, Chia-Chin Li, Chun-Ru Chien
Background. The effectiveness of definitive radiotherapy (RT) for patients with clinical stage IIIB or IIIC lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations who received first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) is unclear. Methods. Taiwan Cancer Registry data were used in this retrospective cohort study to identify adult patients diagnosed with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma between 2011 and 2020. Patients treated with first- or second-generation EGFR TKIs were classified into RT and non-RT groups. Propensity score (PS) weighting was applied to balance covariates between groups. The primary outcome was overall survival (OS), and the incidence of lung cancer mortality (ILCM) was considered as a supplementary outcome. Additional supplementary analyses were conducted to assess the robustness of the findings. Results. Among 270 eligible patients, 41 received RT and 229 did not. After a median follow-up of 46 months, PS-weighted analysis showed the PS-weighted hazard ratio of death for the RT group compared to the non-RT group was 0.94 (95% CI: 0.61–1.45, ). ILCM rates did not differ significantly between the two groups. Supplementary analyses yielded consistent results. Conclusion. The addition of definitive RT to first- or second-generation EGFR TKI treatment does not significantly improve OS of patients with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma. NCT03521154NCT05167851.
背景。对于临床分期为 IIIB 或 IIIC 期、表皮生长因子受体(EGFR)突变并接受过第一代或第二代 EGFR 酪氨酸激酶抑制剂(TKIs)治疗的肺腺癌患者,确定性放疗(RT)的有效性尚不明确。研究方法这项回顾性队列研究使用了台湾癌症登记处的数据,以确定2011年至2020年间确诊为表皮生长因子受体(EGFR)突变的IIIB期或IIIC期肺腺癌的成年患者。接受第一代或第二代EGFR TKIs治疗的患者分为RT组和非RT组。采用倾向评分(PS)加权法平衡各组间的协变量。主要结果是总生存期(OS),肺癌死亡率(ILCM)作为补充结果。为评估研究结果的稳健性,还进行了其他补充分析。研究结果在 270 名符合条件的患者中,41 人接受了 RT 治疗,229 人未接受 RT 治疗。中位随访 46 个月后,PS 加权分析显示,与非 RT 组相比,RT 组的 PS 加权死亡危险比为 0.94(95% CI:0.61-1.45,)。两组的 ILCM 发生率无明显差异。补充分析结果一致。结论在第一代或第二代表皮生长因子受体 TKI 治疗的基础上加用确定性 RT 并不能明显改善表皮生长因子受体突变 IIIB 期或 IIIC 期肺腺癌患者的 OS。NCT03521154NCT05167851.
{"title":"Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors","authors":"Chih-Yen Tu, Te-Chun Hsia, Ying-Chun Lin, Ji-An Liang, Chia-Chin Li, Chun-Ru Chien","doi":"10.1155/2024/8889536","DOIUrl":"https://doi.org/10.1155/2024/8889536","url":null,"abstract":"<i>Background</i>. The effectiveness of definitive radiotherapy (RT) for patients with clinical stage IIIB or IIIC lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations who received first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) is unclear. <i>Methods</i>. Taiwan Cancer Registry data were used in this retrospective cohort study to identify adult patients diagnosed with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma between 2011 and 2020. Patients treated with first- or second-generation EGFR TKIs were classified into RT and non-RT groups. Propensity score (PS) weighting was applied to balance covariates between groups. The primary outcome was overall survival (OS), and the incidence of lung cancer mortality (ILCM) was considered as a supplementary outcome. Additional supplementary analyses were conducted to assess the robustness of the findings. <i>Results</i>. Among 270 eligible patients, 41 received RT and 229 did not. After a median follow-up of 46 months, PS-weighted analysis showed the PS-weighted hazard ratio of death for the RT group compared to the non-RT group was 0.94 (95% CI: 0.61–1.45, <span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.34882 18.973 11.7782\" width=\"18.973pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,11.342,0)\"></path></g></svg><span></span><span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"22.555183800000002 -8.34882 21.921 11.7782\" width=\"21.921pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.605,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,28.845,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,31.809,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,38.051,0)\"></path></g></svg>).</span></span> ILCM rates did not differ significantly between the two groups. Supplementary analyses yielded consistent results. <i>Conclusion</i>. The addition of definitive RT to first- or second-generation EGFR TKI treatment does not significantly improve OS of patients with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma. NCT03521154NCT05167851.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"9 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140032398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway 安罗替尼通过 MET/STAT3/Akt 通路抑制 MCL-1 的表达,从而抑制非小细胞肺癌细胞的顺铂耐药性
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-03-04 DOI: 10.1155/2024/2632014
Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu
Background. Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. Methods. Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay. The mRNA expression levels of mesenchymal-epithelial transition factor (MET) and myeloid cell leukemia-1 (MCL-1) were measured by quantitative real-time PCR. Protein expression levels of MET, MCL-1, and STAT3/Akt pathway-related markers were examined using western blot analysis. Results. Our data showed that anlotinib inhibited the DDP resistance of NSCLC cells by regulating cell proliferation and metastasis. Moreover, MET and MCL-1 expression could be decreased by anlotinib treatment. Silencing of MET suppressed the activity of the STAT3/Akt pathway and MCL-1 expression. Furthermore, MET overexpression reversed the inhibitory effect of anlotinib on the DDP resistance of NSCLC cells, and this effect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway). Conclusion. Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.
背景安罗替尼是一种治疗晚期非小细胞肺癌(NSCLC)的有效靶向药物,已被发现可介导多种癌症的化疗耐药性。然而,安罗替尼介导顺铂(DDP)在NSCLC中耐药的潜在分子机制仍不清楚。研究方法用细胞计数试剂盒 8 评估细胞活力。细胞增殖、迁移和侵袭采用集落形成试验和透孔试验进行测定。间充质-上皮转化因子(MET)和髓样细胞白血病-1(MCL-1)的 mRNA 表达水平采用实时定量 PCR 法进行测定。采用 Western 印迹分析法检测 MET、MCL-1 和 STAT3/Akt 通路相关标记物的蛋白表达水平。结果显示我们的数据显示,安罗替尼通过调节细胞增殖和转移抑制了NSCLC细胞的DDP耐药性。此外,安罗替尼可降低MET和MCL-1的表达。沉默MET可抑制STAT3/Akt通路的活性和MCL-1的表达。此外,MET过表达可逆转安罗替尼对NSCLC细胞DDP耐药性的抑制作用,而MCL-1敲除或ACT001(STAT3/Akt通路抑制剂)可消除这种作用。结论我们的研究结果证实,安罗替尼抑制NSCLC细胞的DDP耐药性,可能是通过介导MET/STAT3/Akt通路来降低MCL-1的表达。
{"title":"Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway","authors":"Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu","doi":"10.1155/2024/2632014","DOIUrl":"https://doi.org/10.1155/2024/2632014","url":null,"abstract":"<i>Background</i>. Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. <i>Methods</i>. Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay. The mRNA expression levels of mesenchymal-epithelial transition factor (MET) and myeloid cell leukemia-1 (MCL-1) were measured by quantitative real-time PCR. Protein expression levels of MET, MCL-1, and STAT3/Akt pathway-related markers were examined using western blot analysis. <i>Results</i>. Our data showed that anlotinib inhibited the DDP resistance of NSCLC cells by regulating cell proliferation and metastasis. Moreover, MET and MCL-1 expression could be decreased by anlotinib treatment. Silencing of MET suppressed the activity of the STAT3/Akt pathway and MCL-1 expression. Furthermore, MET overexpression reversed the inhibitory effect of anlotinib on the DDP resistance of NSCLC cells, and this effect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway). <i>Conclusion</i>. Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"24 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140026315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clustered Cystic Changes in Long-Term Follow-Up Thin-Section Computed Tomographic Findings in Fibrotic Nonspecific Interstitial Pneumonia 纤维化非特异性间质性肺炎长期随访薄层计算机断层扫描结果中的簇状囊性变化
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-02-14 DOI: 10.1155/2024/6665568
Masanori Akira, Narufumi Suganuma
Objectives. The purpose of this study was to retrospectively assess cystic changes in findings on follow-up CT scans of patients with fibrotic nonspecific interstitial pneumonia (NSIP). Methods. The initial and last high-resolution CT scans of 58 patients with pathologically proven fibrotic NSIP were evaluated retrospectively. The median follow-up periods were 48 months (range, 12–183 months). The pattern, extent, and distribution of abnormal CT findings were compared with findings in the same region on previous and subsequent CT scans with a focus on cystic lesions. Results. Cystic lesions in a cluster were shown in 16 patients (28%) with fibrotic NSIP on the last CT scans. Focal clustered cysts were found in 5 cases and diffuse clustered cysts were seen in 11 cases. Focal clustered cysts mimicked honeycombing seen in usual interstitial pneumonia (UIP). Diffuse cysts were uniform in size in 7 of the 11 cases. Traction bronchiectasis in a cluster was seen in 3 of the 7 cases. The clustered cystic changes on CT during the course of NSIP mainly consisted of traction bronchiectasis and bronchiolectasis. Conclusions. Long-standing NSIP did not form honeycombing. The clustered cysts in patients with fibrotic NSIP were mainly remodeling of bronchiectasis.
研究目的本研究旨在回顾性评估纤维化非特异性间质性肺炎(NSIP)患者随访 CT 扫描结果中的囊性变化。研究方法对58例经病理证实的纤维化非特异性间质性肺炎患者的初次和最后一次高分辨率CT扫描结果进行回顾性评估。中位随访时间为 48 个月(12-183 个月)。将异常 CT 结果的模式、范围和分布与之前和之后的 CT 扫描在同一区域的结果进行了比较,重点是囊性病变。结果显示在最近一次 CT 扫描中,16 名(28%)纤维化 NSIP 患者出现了成群的囊性病变。其中 5 例为局灶性簇状囊肿,11 例为弥漫性簇状囊肿。局灶性簇状囊肿与常见间质性肺炎(UIP)中的蜂窝状囊肿相似。在 11 个病例中,7 个病例的弥漫性囊肿大小一致。在 7 例病例中,有 3 例出现了簇状牵引性支气管扩张。在 NSIP 的病程中,CT 上的簇状囊变主要包括牵引性支气管扩张和支气管扩张。结论是久治不愈的 NSIP 不会形成蜂窝状囊肿。纤维化NSIP患者的簇状囊肿主要是支气管扩张的重塑。
{"title":"Clustered Cystic Changes in Long-Term Follow-Up Thin-Section Computed Tomographic Findings in Fibrotic Nonspecific Interstitial Pneumonia","authors":"Masanori Akira, Narufumi Suganuma","doi":"10.1155/2024/6665568","DOIUrl":"https://doi.org/10.1155/2024/6665568","url":null,"abstract":"<i>Objectives</i>. The purpose of this study was to retrospectively assess cystic changes in findings on follow-up CT scans of patients with fibrotic nonspecific interstitial pneumonia (NSIP). <i>Methods</i>. The initial and last high-resolution CT scans of 58 patients with pathologically proven fibrotic NSIP were evaluated retrospectively. The median follow-up periods were 48 months (range, 12–183 months). The pattern, extent, and distribution of abnormal CT findings were compared with findings in the same region on previous and subsequent CT scans with a focus on cystic lesions. <i>Results</i>. Cystic lesions in a cluster were shown in 16 patients (28%) with fibrotic NSIP on the last CT scans. Focal clustered cysts were found in 5 cases and diffuse clustered cysts were seen in 11 cases. Focal clustered cysts mimicked honeycombing seen in usual interstitial pneumonia (UIP). Diffuse cysts were uniform in size in 7 of the 11 cases. Traction bronchiectasis in a cluster was seen in 3 of the 7 cases. The clustered cystic changes on CT during the course of NSIP mainly consisted of traction bronchiectasis and bronchiolectasis. <i>Conclusions</i>. Long-standing NSIP did not form honeycombing. The clustered cysts in patients with fibrotic NSIP were mainly remodeling of bronchiectasis.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2672 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139768882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypersensitivity Pneumonitis: Challenges of a Complex Disease 超敏性肺炎:复杂疾病的挑战
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-01-18 DOI: 10.1155/2024/4919951
Diana Calaras, Aliona David, Eirini Vasarmidi, Katerina Antoniou, Alexandru Corlateanu
Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease caused by chronic inhalation of a wide variety of antigens in susceptible and sensitized individuals, commonly associated with an occupational exposure. An impressive number of inciting antigens causing hypersensitivity pneumonitis have been found to cover a wide range of occupations. As working practices have changed over time, especially in industrialized countries, new names for occupational HP have emerged. This review emphasizes the main diagnostic issues arising from the high variability of clinical presentation and the broad spectrum of causal antigens. Furthermore, it provides an overview of current methods to unveil possible causes of hypersensitivity pneumonitis, highlights HP’s current diagnostic and treatment challenges and the remaining areas of uncertainty, and presents prevention strategies.
超敏性肺炎(HP)是一种复杂的间质性肺部疾病,由易感人群和致敏人群长期吸入多种抗原引起,通常与职业接触有关。引起超敏性肺炎的诱发抗原种类繁多,涉及多种职业。随着时间的推移,特别是在工业化国家,工作方式发生了变化,职业性高过敏性肺炎也出现了新的名称。本综述强调了临床表现的高度可变性和致病抗原的广泛性所带来的主要诊断问题。此外,它还概述了目前揭示超敏性肺炎可能病因的方法,强调了职业性高血压目前在诊断和治疗方面面临的挑战以及尚存在的不确定领域,并介绍了预防策略。
{"title":"Hypersensitivity Pneumonitis: Challenges of a Complex Disease","authors":"Diana Calaras, Aliona David, Eirini Vasarmidi, Katerina Antoniou, Alexandru Corlateanu","doi":"10.1155/2024/4919951","DOIUrl":"https://doi.org/10.1155/2024/4919951","url":null,"abstract":"Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease caused by chronic inhalation of a wide variety of antigens in susceptible and sensitized individuals, commonly associated with an occupational exposure. An impressive number of inciting antigens causing hypersensitivity pneumonitis have been found to cover a wide range of occupations. As working practices have changed over time, especially in industrialized countries, new names for occupational HP have emerged. This review emphasizes the main diagnostic issues arising from the high variability of clinical presentation and the broad spectrum of causal antigens. Furthermore, it provides an overview of current methods to unveil possible causes of hypersensitivity pneumonitis, highlights HP’s current diagnostic and treatment challenges and the remaining areas of uncertainty, and presents prevention strategies.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"1 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139499524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Scale to Assess Humidification during Noninvasive Ventilation: A Prospective Observational Study 评估无创通气过程中湿度的新型量表:前瞻性观察研究
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-12-28 DOI: 10.1155/2023/9958707
Longfang Pan, Yueling Hong, Xiaoqing Zhong, Jiao He, Zuli Zhang, Qianru Zhao, Linfu Bai, Mengyi Ma, Jun Duan
Objective. To develop a novel scale to assess humidification during noninvasive ventilation (NIV). Methods. This study was performed in an ICU of a teaching hospital. Three ICU practitioners with more than 10 years of clinical experience developed an oral humidification scale with a range of 1–4 points. Each studied the current literature on humidification and examined 50 images of mouths of NIV patients with different levels of humidification. Then, through discussion, a consensus scale was developed. Next, 10 practitioners and 33 NIV patients were recruited to validate the scale. Finally, the patients rated the dryness of their mouths using the 1–4 visual scale just after the practitioners’ assessment. Talking and discussion were forbidden during the assessment, and the scorers were blinded to each other. Results. We performed 36 assessments in 33 NIV patients. Three patients were assessed twice each more than 2 days apart. The interitem correlation coefficients between the 10 practitioners ranged from 0.748 to 0.917. Fleiss’s kappa statistic was 0.516, indicating moderate agreement among practitioners. Of the 33 patients, 5 (15%) were unable to make an assessment using the 1–4 visual scale. Among the remainder, 55.7% provided scores that matched those given by the practitioners; 13.7% of scores were 1 point higher than that rated by the practitioners, and 20.7% were 1 point lower. Only 10% were beyond a 1-point difference. The kappa coefficient was 0.483 between patients and practitioners. Conclusions. The oral humidification scale showed moderate agreement between practitioners. It was also highly accurate in reflecting the level of humidification assessed by patients.
目的开发一种新型量表,用于评估无创通气 (NIV) 过程中的加湿情况。方法。本研究在一家教学医院的重症监护室进行。三位拥有 10 年以上临床经验的 ICU 医生制定了口腔湿度评分表,评分范围为 1-4 分。他们各自研究了有关湿度的现有文献,并检查了 50 张不同湿度水平的 NIV 患者口腔图像。然后,通过讨论形成了一个共识量表。接着,招募了 10 名从业人员和 33 名 NIV 患者对量表进行验证。最后,在医生进行评估后,患者使用 1-4 级视觉量表对自己的口腔干燥程度进行评分。评估过程中禁止交谈和讨论,评分者之间互不设盲。结果。我们对 33 名 NIV 患者进行了 36 次评估。有三名患者接受了两次评估,每次相隔两天以上。10 名医生之间的项目间相关系数从 0.748 到 0.917 不等。Fleiss's kappa 统计量为 0.516,表明从业人员之间的一致性适中。在 33 名患者中,有 5 人(15%)无法使用 1-4 视觉量表进行评估。在其余患者中,55.7%的患者提供的评分与医生的评分一致;13.7%的患者的评分比医生的评分高1分,20.7%的患者的评分比医生的评分低1分。只有 10%的差异超过 1 分。患者和医生之间的卡帕系数为 0.483。结论。口腔湿度量表在医生之间显示出中等程度的一致性。该量表在反映患者评估的加湿水平方面也非常准确。
{"title":"A Novel Scale to Assess Humidification during Noninvasive Ventilation: A Prospective Observational Study","authors":"Longfang Pan, Yueling Hong, Xiaoqing Zhong, Jiao He, Zuli Zhang, Qianru Zhao, Linfu Bai, Mengyi Ma, Jun Duan","doi":"10.1155/2023/9958707","DOIUrl":"https://doi.org/10.1155/2023/9958707","url":null,"abstract":"<i>Objective</i>. To develop a novel scale to assess humidification during noninvasive ventilation (NIV). <i>Methods</i>. This study was performed in an ICU of a teaching hospital. Three ICU practitioners with more than 10 years of clinical experience developed an oral humidification scale with a range of 1–4 points. Each studied the current literature on humidification and examined 50 images of mouths of NIV patients with different levels of humidification. Then, through discussion, a consensus scale was developed. Next, 10 practitioners and 33 NIV patients were recruited to validate the scale. Finally, the patients rated the dryness of their mouths using the 1–4 visual scale just after the practitioners’ assessment. Talking and discussion were forbidden during the assessment, and the scorers were blinded to each other. <i>Results</i>. We performed 36 assessments in 33 NIV patients. Three patients were assessed twice each more than 2 days apart. The interitem correlation coefficients between the 10 practitioners ranged from 0.748 to 0.917. Fleiss’s kappa statistic was 0.516, indicating moderate agreement among practitioners. Of the 33 patients, 5 (15%) were unable to make an assessment using the 1–4 visual scale. Among the remainder, 55.7% provided scores that matched those given by the practitioners; 13.7% of scores were 1 point higher than that rated by the practitioners, and 20.7% were 1 point lower. Only 10% were beyond a 1-point difference. The kappa coefficient was 0.483 between patients and practitioners. <i>Conclusions</i>. The oral humidification scale showed moderate agreement between practitioners. It was also highly accurate in reflecting the level of humidification assessed by patients.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"95 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139055798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endobronchial Lipoma: A Rare Cause of Bronchial Stenosis or Obstruction 支气管内脂肪瘤:支气管狭窄或阻塞的罕见原因
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-12-26 DOI: 10.1155/2023/2799436
Jian Chen, Tao Xin, Lei Pan, Yan Li, Weisheng Qian, Jin Wei, Yan Yan, Yan Wang, Faguang Jin, Hua Jiang
Endobronchial lipoma (EL) is a rare benign tumor characterized by tracheobronchial smooth-surfaced mass, often resulting in bronchial obstruction without standard guidelines for management. This study seeks to clarify the clinical features and interventions of EL, aiming to improve its diagnosis and outcomes. A retrospective review was conducted on 28516 outpatients treated between January 2015 and December 2019 at the Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital of Air Force Medical University to collect patients diagnosed with EL. Their clinical, bronchoscopic, chest imaging, and histopathological features along with management were analyzed. Among the patients reviewed, nine were histopathologically diagnosed with EL, comprising seven males and two females. All EL patients exhibited noticeable symptoms, including cough (in eight patients), dyspnea (in six patients), fever (in three patients), expectoration (in two patients), chest pain (in two patients), hemoptysis (in one patient), and fatigue (in one patient). Chest CT abnormalities included endobronchial mass (in four patients), inflammatory exudation (in three patients), atelectasis (in three patients), and infiltration or consolidation (in two patients). In three patients, imaging showed fat density, directly leading to the diagnosis of EL. The EL lesions were distributed with six in the right lung and three in the left lung, all located within the first three subdivisions of the tracheobronchial tree. Treatment approaches varied, with one patient undergoing combined bronchoscopic resection and surgery. The remaining patients received bronchoscopic intervention such as electrosurgical snare resection, argon plasma coagulation (APC), cryotherapy, and holmium laser. Histopathological analysis confirmed the EL diagnosis. Finally, the mass removal restored bronchus patency. Taken together, EL symptoms lack specificity, necessitating reliance on histopathology for EL accurate diagnosis. Bronchoscopic interventions emerge as the preferred option for EL management, surpassing surgical approaches.
支气管内脂肪瘤(EL)是一种罕见的良性肿瘤,其特征是气管支气管表面光滑的肿块,常常导致支气管阻塞,但却没有标准的治疗指南。本研究旨在阐明气管支气管脂肪瘤的临床特征和干预措施,从而改善其诊断和治疗效果。本研究对空军军医大学第二附属医院呼吸与危重症医学科2015年1月至2019年12月期间收治的28516名门诊患者进行了回顾性研究,以收集确诊为EL的患者。分析了他们的临床、支气管镜检查、胸部影像学检查和组织病理学特征以及处理方法。在接受审查的患者中,有 9 人经组织病理学确诊为 EL,其中男性 7 人,女性 2 人。所有 EL 患者都表现出明显的症状,包括咳嗽(8 例)、呼吸困难(6 例)、发热(3 例)、痰多(2 例)、胸痛(2 例)、咯血(1 例)和乏力(1 例)。胸部 CT 异常包括支气管内肿块(4 名患者)、炎性渗出(3 名患者)、肺不张(3 名患者)、浸润或合并(2 名患者)。在三名患者中,成像显示脂肪密度,直接导致了 EL 的诊断。EL病灶的分布情况为右肺六例,左肺三例,均位于气管支气管树的前三个分支。治疗方法各不相同,其中一名患者接受了支气管镜切除和手术联合治疗。其余患者接受了支气管镜介入治疗,如电外科套管切除术、氩等离子凝固术(APC)、冷冻疗法和钬激光。组织病理学分析证实了 EL 的诊断。最后,肿块切除后支气管恢复了通畅。综上所述,EL症状缺乏特异性,因此必须依靠组织病理学才能准确诊断EL。支气管镜干预已成为治疗 EL 的首选方法,超过了外科手术方法。
{"title":"Endobronchial Lipoma: A Rare Cause of Bronchial Stenosis or Obstruction","authors":"Jian Chen, Tao Xin, Lei Pan, Yan Li, Weisheng Qian, Jin Wei, Yan Yan, Yan Wang, Faguang Jin, Hua Jiang","doi":"10.1155/2023/2799436","DOIUrl":"https://doi.org/10.1155/2023/2799436","url":null,"abstract":"Endobronchial lipoma (EL) is a rare benign tumor characterized by tracheobronchial smooth-surfaced mass, often resulting in bronchial obstruction without standard guidelines for management. This study seeks to clarify the clinical features and interventions of EL, aiming to improve its diagnosis and outcomes. A retrospective review was conducted on 28516 outpatients treated between January 2015 and December 2019 at the Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital of Air Force Medical University to collect patients diagnosed with EL. Their clinical, bronchoscopic, chest imaging, and histopathological features along with management were analyzed. Among the patients reviewed, nine were histopathologically diagnosed with EL, comprising seven males and two females. All EL patients exhibited noticeable symptoms, including cough (in eight patients), dyspnea (in six patients), fever (in three patients), expectoration (in two patients), chest pain (in two patients), hemoptysis (in one patient), and fatigue (in one patient). Chest CT abnormalities included endobronchial mass (in four patients), inflammatory exudation (in three patients), atelectasis (in three patients), and infiltration or consolidation (in two patients). In three patients, imaging showed fat density, directly leading to the diagnosis of EL. The EL lesions were distributed with six in the right lung and three in the left lung, all located within the first three subdivisions of the tracheobronchial tree. Treatment approaches varied, with one patient undergoing combined bronchoscopic resection and surgery. The remaining patients received bronchoscopic intervention such as electrosurgical snare resection, argon plasma coagulation (APC), cryotherapy, and holmium laser. Histopathological analysis confirmed the EL diagnosis. Finally, the mass removal restored bronchus patency. Taken together, EL symptoms lack specificity, necessitating reliance on histopathology for EL accurate diagnosis. Bronchoscopic interventions emerge as the preferred option for EL management, surpassing surgical approaches.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"72 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139055699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression 靶向上皮-间质转化的药物治疗气道重塑和肺纤维化进展
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-11-29 DOI: 10.1155/2023/3291957
Hongjuan He, Xiaoyan Ji, Lihua Cao, Zhenzhen Wang, Xiaoyu Wang, Xiu-Min Li, Mingsan Miao
Objective. Dysregulation of epithelial-mesenchymal transition (EMT) in the airway epithelium is associated with airway remodeling and the progression of pulmonary fibrosis. Many treatments have been shown to inhibit airway remodeling and pulmonary fibrosis progression in asthma and chronic obstructive pulmonary disease (COPD) by regulating EMT and have few side effects. This review aimed to describe the development of airway remodeling through the EMT pathway, as well as the potential therapeutic targets in these pathways. Furthermore, this study aimed to review the current research on drugs to treat airway remodeling and their effects on the EMT pathway. Findings. The dysregulation of EMT was associated with airway remodeling in various respiratory diseases. The cytokines released during inflammation may induce EMT and subsequent airway remodeling. Various drugs, including herbal formulations, specific herbal compounds, cytokines, amino acid or protein inhibitors, microRNAs, and vitamins, may suppress airway remodeling by inhibiting EMT-related pathways.
目标。气道上皮上皮间质转化(EMT)的失调与气道重塑和肺纤维化的进展有关。许多治疗方法已被证明通过调节EMT抑制哮喘和慢性阻塞性肺疾病(COPD)的气道重塑和肺纤维化进展,并且几乎没有副作用。本综述旨在描述通过EMT途径进行气道重塑的发展,以及这些途径中潜在的治疗靶点。此外,本研究旨在综述目前治疗气道重塑的药物研究及其对EMT通路的影响。发现。在各种呼吸系统疾病中,EMT的失调与气道重塑有关。炎症期间释放的细胞因子可诱导EMT和随后的气道重塑。各种药物,包括草药配方、特定草药化合物、细胞因子、氨基酸或蛋白质抑制剂、microrna和维生素,可能通过抑制emt相关途径来抑制气道重塑。
{"title":"Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression","authors":"Hongjuan He, Xiaoyan Ji, Lihua Cao, Zhenzhen Wang, Xiaoyu Wang, Xiu-Min Li, Mingsan Miao","doi":"10.1155/2023/3291957","DOIUrl":"https://doi.org/10.1155/2023/3291957","url":null,"abstract":"<i>Objective</i>. Dysregulation of epithelial-mesenchymal transition (EMT) in the airway epithelium is associated with airway remodeling and the progression of pulmonary fibrosis. Many treatments have been shown to inhibit airway remodeling and pulmonary fibrosis progression in asthma and chronic obstructive pulmonary disease (COPD) by regulating EMT and have few side effects. This review aimed to describe the development of airway remodeling through the EMT pathway, as well as the potential therapeutic targets in these pathways. Furthermore, this study aimed to review the current research on drugs to treat airway remodeling and their effects on the EMT pathway. <i>Findings</i>. The dysregulation of EMT was associated with airway remodeling in various respiratory diseases. The cytokines released during inflammation may induce EMT and subsequent airway remodeling. Various drugs, including herbal formulations, specific herbal compounds, cytokines, amino acid or protein inhibitors, microRNAs, and vitamins, may suppress airway remodeling by inhibiting EMT-related pathways.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"278 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138530798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the Diagnostic Performance of Five Clinical Questionnaires for Chronic Obstructive Pulmonary Disease. 五份慢性阻塞性肺疾病临床问卷的诊断效果比较
IF 2.1 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-11-24 eCollection Date: 2023-01-01 DOI: 10.1155/2023/2821056
Alirio R Bastidas, Eduardo Tuta-Quintero, José S Arias, Diana Cufiño, Diana Moya, Daniel Martin, Faure Rodríguez, Carolina Aponte-Murcia, Doris M Pumarejo, Maria A Bejarano, Geraldine Ospina, Lina M Morales, Adriana M Portella, Maria D Barragán, Daniela A Álvarez, José M Hernández

Background: Chronic obstructive pulmonary disease (COPD) remains one of the most prevalent pathologies in the world and is among the leading causes of mortality and morbidity, partially due to underdiagnosis. The use of clinical questionnaires to identify high-risk individuals to take them to further diagnostic procedures has emerged as a strategy to address this problem.

Objective: To compare the performance of the COULD IT BE COPD, CDQ, COPD-PS, LFQ, and PUMA questionnaires for COPD diagnosis.

Methods: A cross-sectional study was carried out on subjects who underwent spirometry in the third-level center. Data were collected between January 2015 and March 2020. Bivariate analysis was performed between the study variables and the presence of COPD. The area under the receiver operating characteristics curve (AUC-ROC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) for each questionnaire were calculated. The AUC-ROCs were compared with the DeLong test, considering a p value <0.05 statistically significant.

Results: 681 subjects met the inclusion criteria and were taken to the final analysis. The prevalence of COPD was 27.5% (187/681). The mean age of the subjects was 65.9 years (SD ± 11.79); 46.3% (315/681) were female, and 83.6% (569/681) reported respiratory symptoms. Statistically significant relationship was found for COPD diagnosis with male sex, older age, respiratory symptoms, and exposure to wood smoke (p value <0.05). The AUC-ROCs of the questionnaires were between 0.581 and 0.681. The COULD IT BE COPD questionnaire had a lower discriminatory capacity AUC-ROC of 0.581, concerning the other scores (DeLong test, p = 0.0002).

Conclusion: The CDQ, COPD-PS, LFQ, PUMA, and COULD IT BE COPD questionnaires have acceptable performance for the diagnosis of COPD together with low sensitivity and specificity. Therefore, its use must be complemented with other diagnostic tests or techniques such as pulmonary function tests.

背景:慢性阻塞性肺疾病(COPD)仍然是世界上最普遍的疾病之一,也是导致死亡率和发病率的主要原因之一,部分原因是诊断不足。使用临床问卷来确定高风险个体,并将其带入进一步的诊断程序,已成为解决这一问题的一种策略。目的:比较COULD IT BE COPD、CDQ、COPD- ps、LFQ和PUMA问卷在COPD诊断中的表现。方法:对在三级中心接受肺活量测定的受试者进行横断面研究。数据收集于2015年1月至2020年3月。在研究变量与COPD存在之间进行双变量分析。计算各问卷的受试者工作特征曲线下面积(AUC-ROC)、敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)、阳性似然比(LR+)、阴性似然比(LR-)。将auc - roc与DeLong检验进行比较,考虑p值。结果:681名受试者符合纳入标准,并进行最终分析。COPD患病率为27.5%(187/681)。受试者平均年龄为65.9岁(SD±11.79);46.3%(315/681)为女性,83.6%(569/681)报告呼吸道症状。COPD诊断与男性、年龄、呼吸系统症状和木材烟雾暴露有统计学意义(p值p = 0.0002)。结论:CDQ、COPD- ps、LFQ、PUMA、COULD IT BE COPD问卷对COPD的诊断性能尚可,但敏感性和特异性较低。因此,它的使用必须辅以其他诊断测试或技术,如肺功能测试。
{"title":"Comparison of the Diagnostic Performance of Five Clinical Questionnaires for Chronic Obstructive Pulmonary Disease.","authors":"Alirio R Bastidas, Eduardo Tuta-Quintero, José S Arias, Diana Cufiño, Diana Moya, Daniel Martin, Faure Rodríguez, Carolina Aponte-Murcia, Doris M Pumarejo, Maria A Bejarano, Geraldine Ospina, Lina M Morales, Adriana M Portella, Maria D Barragán, Daniela A Álvarez, José M Hernández","doi":"10.1155/2023/2821056","DOIUrl":"10.1155/2023/2821056","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) remains one of the most prevalent pathologies in the world and is among the leading causes of mortality and morbidity, partially due to underdiagnosis. The use of clinical questionnaires to identify high-risk individuals to take them to further diagnostic procedures has emerged as a strategy to address this problem.</p><p><strong>Objective: </strong>To compare the performance of the COULD IT BE COPD, CDQ, COPD-PS, LFQ, and PUMA questionnaires for COPD diagnosis.</p><p><strong>Methods: </strong>A cross-sectional study was carried out on subjects who underwent spirometry in the third-level center. Data were collected between January 2015 and March 2020. Bivariate analysis was performed between the study variables and the presence of COPD. The area under the receiver operating characteristics curve (AUC-ROC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) for each questionnaire were calculated. The AUC-ROCs were compared with the DeLong test, considering a <i>p</i> value <0.05 statistically significant.</p><p><strong>Results: </strong>681 subjects met the inclusion criteria and were taken to the final analysis. The prevalence of COPD was 27.5% (187/681). The mean age of the subjects was 65.9 years (SD ± 11.79); 46.3% (315/681) were female, and 83.6% (569/681) reported respiratory symptoms. Statistically significant relationship was found for COPD diagnosis with male sex, older age, respiratory symptoms, and exposure to wood smoke (<i>p</i> value <0.05). The AUC-ROCs of the questionnaires were between 0.581 and 0.681. The COULD IT BE COPD questionnaire had a lower discriminatory capacity AUC-ROC of 0.581, concerning the other scores (DeLong test, <i>p</i> = 0.0002).</p><p><strong>Conclusion: </strong>The CDQ, COPD-PS, LFQ, PUMA, and COULD IT BE COPD questionnaires have acceptable performance for the diagnosis of COPD together with low sensitivity and specificity. Therefore, its use must be complemented with other diagnostic tests or techniques such as pulmonary function tests.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2023 ","pages":"2821056"},"PeriodicalIF":2.1,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138476753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Sleep-Disordered Breathing in Prader-Willi Syndrome. Prader-Willi综合征睡眠呼吸障碍的患病率。
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-10-26 eCollection Date: 2023-01-01 DOI: 10.1155/2023/9992668
Ahmed Abushahin, Amal Al-Naimi, Mutasim Abu-Hasan, Rania Arar, M Lina Hayati, Antonisamy Belavendra, Ibrahim A Janahi

Introduction: Sleep-disordered breathing (SDB) is common in patients with Prader-Willi Syndrome (PWS). However, the prevalence of SDB varies widely between studies. Early identification of SDB and factors contributing to its incidence is essential, particularly when considering growth hormone (GH) therapy.

Objectives: The aims of the study were to describe the prevalence and phenotypes of sleep-disordered breathing (SDB) in patients with Prader-Willi syndrome (PWS) and to determine the effects of age, gender, symptoms, GH therapy and body mass index on SDB severity.

Methods: This study was a retrospective chart review of all patients with genetically confirmed Prader-Willi syndrome who underwent diagnostic overnight polysomnography (PSG) in the sleep laboratory at Sidra Medicine. Clinical and PSG data of enrolled patients were collected.

Results: We identified 20 patients (nine males, eleven females) with PWS who had overnight sleep polysomnography (PSG) at a median age (IQR) of 5.83 (2.7-12) years. The median apnea-hypopnea index (AHI) was 8.55 (IQR 5.8-16.9) events/hour. The median REM-AHI was 27.8 (IQR 15-50.6) events/hour. The median obstructive apnea-hypopnea index (OAHI) was 7.29 (IQR 1.8-13.5) events/hour. The median central apnea-hypopnea index (CAHI) was 1.77 (IQR 0.6-4.1) events/hour. Nineteen patients (95%) demonstrated SDB by polysomnography (PSG) based on AHI ≥1.5 events/hour. Nine patients (45%) were diagnosed with obstructive sleep apnea (OSA). Three patients (15%) were diagnosed with central sleep apnea (CSA). Seven patients (35%) were diagnosed with mixed sleep apnea. No correlations were observed between AHI and age, gender, BMI, symptoms, or GH therapy. However, REM-AHI was significantly correlated with BMI (P=0.031).

Conclusion: This study shows a high prevalence of SDB among our patients with PWS. Obstructive sleep apnea was the predominant phenotype. BMI was the only predictor for high REM-AHI. Further studies of large cohorts are warranted to define SDB in PWS and design the appropriate treatment.

引言:睡眠呼吸障碍(SDB)在Prader-Willi综合征(PWS)患者中很常见。然而,不同研究的SDB患病率差异很大。早期识别SDB及其发病因素至关重要,尤其是在考虑生长激素(GH)治疗时。目的:本研究旨在描述Prader-Willi综合征(PWS)患者睡眠呼吸障碍(SDB)的患病率和表型,并确定年龄、性别、症状、生长激素治疗和体重指数对SDB严重程度的影响。方法:本研究是对所有在Sidra Medicine睡眠实验室接受诊断性夜间多导睡眠图(PSG)的遗传确诊的Prader-Willi综合征患者的回顾性图表回顾。收集入选患者的临床和PSG数据。结果:我们确定了20名PWS患者(9名男性,11名女性),他们在中位年龄(IQR)为5.83(2.7-12)岁时进行了夜间睡眠多导睡眠图(PSG)检查。中位呼吸暂停低通气指数(AHI)为8.55(IQR 5.8-16.9)次/小时。REM-AHI的中位数为27.8(IQR 15-50.6)次/小时。阻塞性呼吸暂停低通气指数(OAHI)中位数为7.29(IQR 1.8-13.5)次/小时。中位中枢性呼吸暂停低通气指数(CAHI)为1.77(IQR 0.6-4.1)次/小时。19名患者(95%)通过基于AHI≥1.5事件/小时的多导睡眠图(PSG)显示SDB。9名患者(45%)被诊断为阻塞性睡眠呼吸暂停(OSA)。3名患者(15%)被诊断为中枢性睡眠呼吸暂停(CSA)。7名患者(35%)被诊断为混合性睡眠呼吸暂停。AHI与年龄、性别、BMI、症状或GH治疗之间没有相关性。然而,REM-AHI与BMI显著相关(P=0.031)。结论:本研究表明,在我们的PWS患者中,SDB的患病率很高。阻塞性睡眠呼吸暂停是主要表型。BMI是高REM-AHI的唯一预测因素。有必要对大型队列进行进一步研究,以确定PWS中的SDB并设计适当的治疗方法。
{"title":"Prevalence of Sleep-Disordered Breathing in Prader-Willi Syndrome.","authors":"Ahmed Abushahin,&nbsp;Amal Al-Naimi,&nbsp;Mutasim Abu-Hasan,&nbsp;Rania Arar,&nbsp;M Lina Hayati,&nbsp;Antonisamy Belavendra,&nbsp;Ibrahim A Janahi","doi":"10.1155/2023/9992668","DOIUrl":"https://doi.org/10.1155/2023/9992668","url":null,"abstract":"<p><strong>Introduction: </strong>Sleep-disordered breathing (SDB) is common in patients with Prader-Willi Syndrome (PWS). However, the prevalence of SDB varies widely between studies. Early identification of SDB and factors contributing to its incidence is essential, particularly when considering growth hormone (GH) therapy.</p><p><strong>Objectives: </strong>The aims of the study were to describe the prevalence and phenotypes of sleep-disordered breathing (SDB) in patients with Prader-Willi syndrome (PWS) and to determine the effects of age, gender, symptoms, GH therapy and body mass index on SDB severity.</p><p><strong>Methods: </strong>This study was a retrospective chart review of all patients with genetically confirmed Prader-Willi syndrome who underwent diagnostic overnight polysomnography (PSG) in the sleep laboratory at Sidra Medicine. Clinical and PSG data of enrolled patients were collected.</p><p><strong>Results: </strong>We identified 20 patients (nine males, eleven females) with PWS who had overnight sleep polysomnography (PSG) at a median age (IQR) of 5.83 (2.7-12) years. The median apnea-hypopnea index (AHI) was 8.55 (IQR 5.8-16.9) events/hour. The median REM-AHI was 27.8 (IQR 15-50.6) events/hour. The median obstructive apnea-hypopnea index (OAHI) was 7.29 (IQR 1.8-13.5) events/hour. The median central apnea-hypopnea index (CAHI) was 1.77 (IQR 0.6-4.1) events/hour. Nineteen patients (95%) demonstrated SDB by polysomnography (PSG) based on AHI ≥1.5 events/hour. Nine patients (45%) were diagnosed with obstructive sleep apnea (OSA). Three patients (15%) were diagnosed with central sleep apnea (CSA). Seven patients (35%) were diagnosed with mixed sleep apnea. No correlations were observed between AHI and age, gender, BMI, symptoms, or GH therapy. However, REM-AHI was significantly correlated with BMI (<i>P</i>=0.031).</p><p><strong>Conclusion: </strong>This study shows a high prevalence of SDB among our patients with PWS. Obstructive sleep apnea was the predominant phenotype. BMI was the only predictor for high REM-AHI. Further studies of large cohorts are warranted to define SDB in PWS and design the appropriate treatment.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2023 ","pages":"9992668"},"PeriodicalIF":2.2,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Conservative Oxygen Therapy versus Conventional Oxygen Therapy on the Mortality in ICU Patients: A Meta-Analysis. 保守氧疗与常规氧疗对ICU患者死亡率的影响:Meta分析。
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2023-10-14 eCollection Date: 2023-01-01 DOI: 10.1155/2023/7023712
Xinyu Jiang, Dong Qiu

Objective: To compare the effects of conservative oxygen therapy and conventional oxygen therapy on the mortality of critically ill patients in ICU.

Methods: Searching for randomized controlled clinical trials (RCT) on the effect of conservative oxygen therapy and conventional oxygen therapy on the mortality of critically ill patients in computer databases, including PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang, with postdate before August 2022. We have two researchers evaluating the quality of the literature included and extracting data as per the inclusion and exclusion criteria and then analyzed it with RevMan 5.4 statistical software. Primary outcome included short-term mortality (28-day mortality or ICU mortality); secondary outcome included 90-day mortality, ICU length of stay, hospital length of stay, incidence of new organ dysfunction in ICU, incidence of new infection in ICU, and incidence of ICUAW.

Results: A total of 5779 subjects were included in 10 articles, including 2886 in the conservative oxygen therapy group and 2893 in the conventional oxygen therapy group. The meta-analysis showed that conservative oxygen therapy had an advantage over conventional oxygen therapy in terms of short-term mortality (P=0.03). Subgroup analysis based on different conservative oxygen targets showed that this advantage was statistically significant when the target is set above 90% (RR = 0.76, 95% CI = 0.62∼0.94, P=0.01), while there was no significant difference between conservative oxygen therapy and conventional oxygen therapy when the target is set below 90% (RR = 0.95, 95% CI = 0.79∼1.16, P=0.63). In addition, in terms of the incidence of new infections in the ICU (P=0.03) and the incidence of ICUAW (P=0.03), conservative oxygen therapy also had advantages over conventional oxygen therapy, and the difference was statistically significant. But in terms of 90-day mortality (P=0.61), ICU length of stay (P=0.96), hospital length of stay (P=0.47), and incidence of new organ dysfunction in ICU (P=0.61), there was no significant difference between conservative oxygen therapy and conventional oxygen therapy.

Conclusion: Compared with conventional oxygen therapy, conservative oxygen therapy can reduce the short-term mortality of severe patients, especially when the conservative oxygen therapy target is set above 90%. And it can also reduce the incidence of ICU new infections and ICUAW, while having no effect on 90-day mortality, ICU length of stay, and hospital length of stay.

目的:比较保守氧疗和常规氧疗对ICU危重患者死亡率的影响。方法:在PubMed、Embase、,Cochrane图书馆、中国知网、VIP和万方,发布日期在2022年8月之前。我们有两名研究人员根据纳入和排除标准评估纳入文献的质量并提取数据,然后使用RevMan 5.4统计软件进行分析。主要转归包括短期死亡率(28天死亡率或ICU死亡率);次要转归包括90天死亡率、ICU住院时间、住院时间、ICU新器官功能障碍发生率、ICU新感染发生率和ICUAW发生率。荟萃分析显示,就短期死亡率而言,保守氧疗比传统氧疗具有优势(P=0.03)。基于不同保守氧靶点的亚组分析显示,当靶点设定在90%以上时,这种优势具有统计学意义(RR = 0.76,95%CI = 0.62~0.94,P=0.01),而当目标设定在90%以下时,保守氧疗和常规氧疗之间没有显著差异(RR = 0.95,95%CI = 0.79~1.16,P=0.63)。此外,在ICU新感染的发生率(P=0.03)和ICUAW的发生率方面,保守氧疗也比传统氧疗有优势,差异具有统计学意义。但就90天死亡率(P=0.61)、ICU住院时间(P=0.96)、住院时间(P=0.047)和ICU新器官功能障碍发生率(P=0.61%)而言,保守氧疗与常规氧疗之间没有显著差异。结论:与常规氧疗相比,保守氧疗可以降低重症患者的短期死亡率,尤其是当保守氧疗目标设定在90%以上时。它还可以降低ICU新感染和ICUAW的发生率,同时对90天死亡率、ICU住院时间和住院时间没有影响。
{"title":"Effects of Conservative Oxygen Therapy versus Conventional Oxygen Therapy on the Mortality in ICU Patients: A Meta-Analysis.","authors":"Xinyu Jiang,&nbsp;Dong Qiu","doi":"10.1155/2023/7023712","DOIUrl":"10.1155/2023/7023712","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effects of conservative oxygen therapy and conventional oxygen therapy on the mortality of critically ill patients in ICU.</p><p><strong>Methods: </strong>Searching for randomized controlled clinical trials (RCT) on the effect of conservative oxygen therapy and conventional oxygen therapy on the mortality of critically ill patients in computer databases, including PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang, with postdate before August 2022. We have two researchers evaluating the quality of the literature included and extracting data as per the inclusion and exclusion criteria and then analyzed it with RevMan 5.4 statistical software. Primary outcome included short-term mortality (28-day mortality or ICU mortality); secondary outcome included 90-day mortality, ICU length of stay, hospital length of stay, incidence of new organ dysfunction in ICU, incidence of new infection in ICU, and incidence of ICUAW.</p><p><strong>Results: </strong>A total of 5779 subjects were included in 10 articles, including 2886 in the conservative oxygen therapy group and 2893 in the conventional oxygen therapy group. The meta-analysis showed that conservative oxygen therapy had an advantage over conventional oxygen therapy in terms of short-term mortality (<i>P</i>=0.03). Subgroup analysis based on different conservative oxygen targets showed that this advantage was statistically significant when the target is set above 90% (RR = 0.76, 95% CI = 0.62∼0.94, <i>P</i>=0.01), while there was no significant difference between conservative oxygen therapy and conventional oxygen therapy when the target is set below 90% (RR = 0.95, 95% CI = 0.79∼1.16, <i>P</i>=0.63). In addition, in terms of the incidence of new infections in the ICU (<i>P</i>=0.03) and the incidence of ICUAW (<i>P</i>=0.03), conservative oxygen therapy also had advantages over conventional oxygen therapy, and the difference was statistically significant. But in terms of 90-day mortality (<i>P</i>=0.61), ICU length of stay (<i>P</i>=0.96), hospital length of stay (<i>P</i>=0.47), and incidence of new organ dysfunction in ICU (<i>P</i>=0.61), there was no significant difference between conservative oxygen therapy and conventional oxygen therapy.</p><p><strong>Conclusion: </strong>Compared with conventional oxygen therapy, conservative oxygen therapy can reduce the short-term mortality of severe patients, especially when the conservative oxygen therapy target is set above 90%. And it can also reduce the incidence of ICU new infections and ICUAW, while having no effect on 90-day mortality, ICU length of stay, and hospital length of stay.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2023 ","pages":"7023712"},"PeriodicalIF":2.2,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49688807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian respiratory journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1